Bayer Taps Deeper Into Beijing’s Biotech Potential, Renews Partnership With Tsinghua
This article was originally published in PharmAsia News
Latest research deal for Bayer underscores Beijing’s growing importance as a biotech hub.
You may also be interested in...
One year after opening its Innovation Center in Mission Bay, Calif., Bayer is opening the space to start-ups to help establish their research labs.
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt
SHANGHAI - China's pharma market is expected to continue to grow in the next five years with a CAGR of 23.2%, which will be backed largely by the expansion of community health centers across tier 2 and tier 3 cities, according to a report issued by consultancy IMS Health